Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone in patients with Mycosis Fungoides.
This statement is based on a regulatory approval from the Health Canada:
ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy